Vericel Forecasts $330M-$340M Revenue for 2026 and Announces Share Repurchase Program
Vericel (NASDAQ: VCEL) reported record second-quarter revenue of over $77 million, a 22% increase compared to the same period last year. The company has raised its full-year revenue guidance to $330 million for 2026 and also announced a new share repurchase program worth up to $200 million. The strong performance reflects robust demand for Vericel's cell therapy products, particularly in orthopedics and oncology. The updated financial outlook signals confidence from management regarding the company’s growth trajectory and operational momentum. This move is expected to bolster investor sentiment by demonstrating a commitment to returning value to shareholders while maintaining focus on long-term revenue expansion.
Tickers: $VCEL
Topics: biotech finance pharmaceuticals